NTX1107

NTX1107 is an antibody-drug conjugate (ADC) being developed by Nectin Therapeutics for the treatment of solid and hematological malignancies. It is designed to deliver a cytotoxic payload directly to tumor cells expressing a specific antigen, which is currently undisclosed by the developer (though some industry reports suggest a target within the nectin or nectin-like family). By combining the targeting specificity of a monoclonal antibody with the potent cell-killing ability of a cytotoxic agent, NTX1107 aims to overcome resistance in various cancers. The program is currently in the IND-enabling stage of development, representing a key component of Nectin Therapeutics' pipeline of next-generation cancer therapies.